Citations

Clear

171 citation(s) found for "Moss, M".

Donation after circulatory death transplant outcomes using livers recovered by local surgeons
Macdonough, Elizabeth , Pont, Kylie , Valenti, Kristi , Lizaola‐Mayo, Blanca , Brooks, Abigail , Das, Devika , Heilman, Raymond L. , Mathur, Amit K. , Hewitt, Winston R. , Moss, Adyr A. , Aqel, Bashar , Reddy, Kunam S. , Jadlowiec, Caroline , Macdonough, Elizabeth , Pont, Kylie , Valenti, Kristi , Lizaola-Mayo, Blanca , Brooks, Abigail , Das, Devika , Heilman, Raymond , Mathur, Amit , Hewitt, Winston , Moss, Adyr , Aqel, Bashar A. , Reddy, Kunam S , Jadlowiec, Caroline C.

Mayo Clinic

Liver Transplantation | March 25, 2022 | Volume: 28 | Issue: 11 | Pages: 1726-1734

10.1002/lt.26461 | PMID 35332655 Get It

Abstract Donation after circulatory death (DCD) liver transplantation (LT) outcomes have been attributed to multiple variables, including procurement surgeon recovery techniques. Outcomes of 196 DCD LTs at Mayo Clinic Arizona were analyzed based on graft recovery by a surgeon from our center (transplant procurement team [TPT]) versus a local procurement surgeon (non‐TPT [NTPT]). A standard recovery technique was used for all TPT livers. The recovery technique used by the NTPT was left to the discretion of that surgeon. A total of 129 (65.8%) grafts were recovered by our TPT, 67 (34.2%) by the NTPT. Recipient age (p = 0.43), Model for End‐Stage Liver Disease score (median 17 vs. 18; p = 0.22), and donor warm ischemia time (median 21.0 vs. 21.5; p = 0.86) were similar between the TPT and NTPT groups. NTPT livers had longer cold ischemia times (6.5 vs. 5.0 median hours; p < 0.001). Early allograft dysfunction (80.6% vs. 76.1%; p = 0.42) and primary nonfunction (0.8% vs. 0.0%; p = 0.47) were similar. Ischemic cholangiopathy (IC) treated with endoscopy occurred in 18.6% and 11.9% of TPT and NTPT grafts (p = 0.23). At last follow‐up, approximately half of those requiring endoscopy were undergoing a stent‐free trial (58.3% TPT; 50.0% NTPT; p = 0.68). IC requiring re‐LT in the first year occurred in 0.8% (n = 1) of TPT and 3.0% (n = 2) of NTPT grafts (p = 0.23). There were no differences in patient (hazard ratio [HR], 1.95; 95% confidence interval [CI], 0.76–5.03; p = 0.23) or graft (HR, 1.99; 95% CI, 0.98–4.09; p = 0.10) survival rates. Graft survival at 1 year was 91.5% for TPT grafts and 95.5% for NTPT grafts. Excellent outcomes can be achieved using NTPT for the recovery of DCD livers. There may be an opportunity to expand the use of DCD livers in the United States by increasing the use of NTPT.
Duration Of Delayed Graft Function And Its Impact On Graft Outcomes In Deceased Donor Kidney Transplantation Running Head: Impact of Duration of Delayed Graft Function
Reddy, Kunam S. , Butterfield, Richard , Moss, Adyr A. , Khamash, Hassan A., Kodali, Lavanya , Misra, Suman , Heilman, Raymond L. , Budhiraja, Pooja , Jadlowiec, Caroline C.

Mayo Clinic

No container title available | February 9, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1277907/v1 Get It

Abstract Background. There is controversy regarding the impact of delayed graft function (DGF) on kidney transplant outcomes. We hypothesize that the duration of DGF, rather than DGF itself, is associated with long-term kidney graft function.Methods. We analyzed all deceased donor kidney transplants (DDKT) done at our center between 2008 to 2020 with DGF to determine factors associated with DGF duration as well as the impact of DGF duration on 1) acute rejection, BKV infection, progression of fibrosis on protocol biopsy, and death censored graft survival 2) resource utilization, including hospital length of stay and readmissions. DGF duration was assessed at three 14-day intervals: <14 DGF days, 14-27 DGF days, >28 DGF days.Results. There were 1714 DDKT were included, 59.4% (n=1018) had DGF. The median DGF duration was 10 days IQR (6,15). The majority of recipients (95%) had resolution of DGF within 28 days. Donor factors associated with DGF days were longer cold ischemia time, donor on inotropes, older age, donation after circulatory death, higher terminal creatinine, and hypertension. Recipient factors associated with increased DGF duration included male sex, length on dialysis before transplant, and higher body mass index. There were no differences in acute rejection events or interstitial fibrosis progression by 4 months when comparing DGF days. The median length of stay was 3 days. However, readmissions increased with increasing DGF duration. Death-censored graft survival was not associated with the length of DGF except when DGF lasted >28 days. Conclusions. Inferior graft survival was observed only in recipients of DDKT with DGF lasting beyond 28 days. DGF lasting <28 days had no impact on graft survival. Duration of DGF, rather than DGF itself, is associated with graft survival. Trial Registration. Retrospective study approved by Mayo Clinic IRB.
Immunotherapy as a Downstaging Tool for Liver Transplantation in Hepatocellular Carcinoma
Mathur, Amit K. , Borad, M.J., Lam‐Himlin, Dora , Corey, Rebecca, Iqbal, Sara , Okubo, Keita , Byrne, Thomas , Moss, Adyr A. , Aqel, Bashar , Chascsa, David M. , Lizaola-Mayo, Blanca C, Lam-Himlin, Dora M, Corey, Rebecca L, Byrne, Thomas J., Lizaola‐Mayo, Blanca , Jadlowiec, Caroline C. , Iqbal, Sara, Aqel, Bashar A.

Mayo Clinic

American Journal of Gastroenterology | February 8, 2022 | Volume: 116 | Issue: 12 | Pages: 2478-2480

10.14309/ajg.0000000000001391 | PMID 35134013 Get It

Solid Organ Transplantation From SARS-CoV-2–infected Donors to Uninfected Recipients: A Single-center Experience
Jayasekera, Channa R., Vikram, Holenarasipur R., Rifat, Zeeshan, Wagler, Josiah, Okubo, Keita, Braaksma, Brandon R., Harbell, Jack W., Jadlowiec, Caroline C., Katariya, Nitin N., Mathur, Amit K., Moss, Adyr, Reddy, K. Sudhakar, Singer, Andrew, Orenstein, Robert, Saling, Christopher F., Seville, Maria T., Mour, Girish K., Vargas, Hugo E., Byrne, Thomas J., Hewitt, Winston R., Aqel, Bashar A., Vargas, Hugo E. , Vikram, Holenarasipur R. , Katariya, Nitin , Vikram, Holenarasipur R. , Vargas, Hugo E , Katariya, Nitin N , Jayasekera, Channa R., Rifat, Zeeshan, Wagler, Josiah, Okubo, Keita, Braaksma, Brandon R., Harbell, Jack W., Jadlowiec, Caroline C., Mathur, Amit K., Moss, Adyr, Reddy, K. Sudhakar, Singer, Andrew, Orenstein, Robert, Saling, Christopher F., Seville, Maria T., Mour, Girish K., Byrne, Thomas J., Hewitt, Winston R., Aqel, Bashar A., Okubo, Keita

Mayo Clinic

Transplantation Direct | January 13, 2022 | Volume: 8 | Issue: 2 | Pages: e1286

10.1097/txd.0000000000001286 | PMID 35047665 Get It

Background. The risk of donor-derived severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in solid organ (heart, lung, liver, kidney, pancreas, and intestine) transplant recipients is poorly understood. Since hematogenous transmission of SARS-CoV-2 has not been documented to date, nonlung solid organs might be suitable for transplantation since they likely portend a low risk of viral transmission. Methods. Abdominal solid organs from SARS-CoV-2–infected donors were transplanted into uninfected recipients. Results. Between April 18, 2021, and October 30, 2021, we performed transplants of 2 livers, 1 simultaneous liver and kidney, 1 kidney, and 1 simultaneous kidney and pancreas from SARS-CoV-2–infected donors into 5 uninfected recipients. None of the recipients developed SARS-CoV-2 infection or coronavirus disease 2019, and when tested, allograft biopsies showed no evidence of SARS-CoV-2 RNA. Conclusions. Transplanting nonlung organs from SARS-CoV-2–infected donors into uninfected recipients demonstrated no evidence of virus transmission.
Comparing Diagnosis and Treatment of Pulmonary Hypertension Patients at a Pulmonary Hypertension Center versus Community Centers
Saunders, Hollie , Helgeson, Scott A. , Abdelrahim, Ahmed, Rottman-Pietrzak, Kathleen, Reams, Victoria , Zeiger, Tonya K., Moss, John E. , Burger, Charles D. , Helgeson, Scott A , Burger, Charles , Abdelrahim, Ahmed

Mayo Clinic

Diseases | January 7, 2022 | Volume: 10 | Issue: 1 | Pages: 5

10.3390/diseases10010005 | PMID 35076491 Get It

Once patients are diagnosed with pulmonary hypertension it is important to identify the correct diagnostic group as it will have implications on the disease state management. Pulmonary hypertension is increasingly diagnosed and treated in general medical practices; however, evidence-based guidelines recommend evaluation and treatment in pulmonary hypertension centers for accurate diagnosis and appropriate treatment recommendations. We conducted a retrospective cohort study of 509 random patients 18 years and older who were evaluated in our pulmonary hypertension clinic from January 2005 to December 2018. 68.4% (n = 348) had their diagnostic group clarified or changed. Pulmonary hypertension was deemed an incorrect diagnosis in 12.4% (n = 63). A total of 114 patients (22.4%) had been initiated on pulmonary hypertension specific treatment prior to presentation. Pulmonary hypertension specific medication was stopped in 57 (50.0%) cases. The estimated monthly saving of the stopped medication based on wholesale acquisition costs was USD 396,988.05–419,641.05, a monthly saving of USD 6964.70–7362.12 per patient. Evaluation outside of a pulmonary hypertension center may lead to misdiagnosis and inappropriate or inadequate treatment. Pulmonary arterial hypertension directed therapy improves median survival, but inappropriate therapy may cause harm; therefore, patients benefit from a specialized center with multiple resources to secure an accurate diagnosis and tailored treatment for their condition.
Health‐related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: an analysis from the Pulmonary Hypertension Association Registry (PHAR)
Minhas, Jasleen , Narasimmal, S.P., Bull, Todd M., Marco, Teresa De , McConnell, John W., Lammi, Matthew R. , Thenappan, Thenappan , Feldman, Jeremy P., Sager, Jeffrey S., Badesch, David B., Ryan, John , Grinnan, Daniel, Zwicke, Dianne, Elwing, Jean , Moss, John E. , Eggert, Michael, Shlobin, Oksana A. , Bartolome, Sonja, Mathai, Stephen C. , Mazimba, Sula , Pugliese, Steven C. , Al‐Naamani, Nadine , investigators, PHAR, P Frantz, Robert, Thenappan, Thenappan , Minhas, Jasleen , Al-Naamani, Nadine , Mathai, Stephen C , Grinnan, D. , Horn, Evelyn M. , Frantz, Robert P. , investigators, PHAR

Mayo Clinic

Pulmonary Circulation | October 1, 2021 | Volume: 11 | Issue: 4 | Pages: 1-11

10.1177/20458940211053196 | PMID 34671455 Get It

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, morbid, potentially curable subtype of pulmonary hypertension that negatively impacts health‐related quality of life (HRQoL). Little is known about differences in HRQoL and hospitalization between CTEPH patients and idiopathic pulmonary arterial hypertension (IPAH) patients. Using multivariable linear regression and mixed effects models, we examined differences in HRQoL assessed by emPHasis‐10 (E10) and SF‐12 between CTEPH and IPAH patients in the Pulmonary Hypertension Association Registry, a prospective multicenter cohort of patients newly evaluated at a Pulmonary Hypertension Care Center. Multivariable negative binomial regression models were used to estimate incidence rate ratios (IRR) for hospitalization amongst the two groups. We included 461 IPAH patients and 169 CTEPH patients. Twenty‐one percent of CTEPH patients underwent pulmonary thromboendarterectomy (PTE) before the end of follow‐up. At baseline, patients with CTEPH had significantly worse HRQoL (higher E10 scores) (ß 2.83, SE 1.11, p = 0.01); however, differences did not persist over time. CTEPH patients had higher rates of hospitalization (excluding the hospitalization for PTE) compared to IPAH patients after adjusting for age, sex, body mass index, WHO functional class and six‐minute walk distance (IRR 1.66, 95%CI 1.04–2.65, p = 0.03). CTEPH patients who underwent PTE had improved HRQoL as compared to those who were medically managed, but patients who underwent PTE were younger, had higher cardiac outputs and greater six‐minute walk distances. In this large, prospective, multicenter cohort, CTEPH patients had significantly worse baseline HRQoL and higher rates of hospitalizations than those with IPAH. CTEPH patients who underwent PTE had significant improvements in HRQoL.
Successful outcomes with transplanting kidneys from deceased donors with acute kidney injuryon temporary renal replacement therapy
Budhiraja, Pooja , Heilman, Raymond L. , Ryan, Margaret , Khamash, Hasan , Kodali, Lavanya , Moss, Adyr A. , Mathur, Amit K. , Reddy, Kunam S. , Jadlowiec, Caroline , Ryan, Margaret S, Khamash, Hasan A, Mathur, Amit , Budhiraja, Pooja , Jadlowiec, Caroline C. , Smith, Maxwell L.

Mayo Clinic

Clinical Transplantation | September 13, 2021 | Volume: 35 | Issue: 12 | Pages: No page available

10.1111/ctr.14465 | PMID 34514643 Get It

AbstractBackground and objectivesWe aimed to determine outcomes with transplanting kidneys from deceased donors with severe acute kidney injury requiring acute renal replacement therapy (RRT).Materials and methodsA total of 172 recipients received a kidney from donors with acute kidney injury stage 3 (AKIN3) requiring RRT. We compared the study group to 528 recipients who received a kidney from donors with AKIN stage 3 not on RRT and 463 recipients who received < 85% Kidney Donor Profile Index (KDPI) AKIN stage 0 kidney.ResultsThe study group donors were younger compared to the 2 control groups. Despite higher DGF in the study group, the length of hospital stay and acute rejection were similar. Death censored graft survival (96% AKIN3‐RRT vs. 97%AKIN3 no RRT vs. 96% KDPI < 85% AKIN0,P = 0.26) and patient survival with functioning graft at 1 year (95% across all groups,P = 0.402) were similar. The estimated glomerular filtration rate were similar across the 3 groups after first month. Interstitial fibrosis and tubular atrophy score ≥ 2 on protocol biopsy at time 0, 4 and 12 months were similar. Primary nonfunction was rare and associated with high KDPI.ConclusionsTransplanting selected kidneys from deceased donors with AKIN3 requiring RRT is safe and has good outcomes.
Voice Therapy According to the Rehabilitation Treatment Specification System: Expert Consensus Ingredients and Targets
Stan, Jarrad H. Van , Barkmeier‐Kraemer, Julie , Doyle, Patricia, Gherson, Shirley , Kelchner, Lisa , Muise, Jason, Petty, Brian , Roy, Nelson , Stemple, Joseph C., Tolejano, Carol Jorgensen, Van Stan, Jarrad H , Roy, Nelson , Whyte, John , Duffy, Joseph R. , Thibeault, Susan L.

Mayo Clinic

American Journal of Speech-Language Pathology | August 31, 2021 | Volume: 30 | Issue: 5 | Pages: 2169-2201

10.1044/2021_ajslp-21-00076 | PMID 34464550 Get It

Purpose Clinical trials have demonstrated that standardized voice treatment programs are effective for some patients, but identifying the unique individual treatment ingredients specifically responsible for observed improvements remains elusive. To address this problem, the authors used a taxonomy of voice therapy, the Rehabilitation Treatment Specification System (RTSS), and a Delphi process to develop the RTSS-Voice (expert consensus categories of measurable and unique voice treatment ingredients and targets). Method Initial targets and ingredients were derived from a taxonomy of voice therapy. Through six Delphi Rounds, 10 vocal rehabilitation experts rated the measurability and uniqueness of individual treatment targets and ingredients. After each round, revisions (guided by the experts' feedback) were finalized among a primary reader (a voice therapy expert) and two external readers (rehabilitation experts outside the field of voice). Consensus was established when the label and definition of an ingredient or target reached a supramajority threshold (≥ 8 of 10 expert agreement). Results Thirty-five target and 19 ingredient categories were agreed to be measurable, unique, and accurate reflections of the rules and terminology of the RTSS. Operational definitions for each category included differences in the way ingredients are delivered and the way individual targets are modified by those ingredients. Conclusions The consensus labels and operationalized ingredients and targets making up the RTSS-Voice have potential to improve voice therapy research, practice, and education/training. The methods used to develop these lists may be useful for other speech, language, and hearing treatment specifications. Supplemental Material https://doi.org/10.23641/asha.15243357
Guidelines for Conducting Ethical Artificial Intelligence Research in Neurology
Chiong, Winston , Goldenholz, Daniel M. , Chiang, Sharon, Picard, Rosalind W, Moss, Robert, Goldenholz, Daniel M , Chiang, Sharon , Picard, Rosalind W. , MOSS, ROBERT E. , Worrell, Gregory A. , Rao, Vikram R.

Mayo Clinic

Neurology | July 27, 2021 | Volume: 97 | Issue: 13 | Pages: 632-640

10.1212/wnl.0000000000012570 | PMID 34315785 Get It

Variation in opioid prescribing patterns after abdominal transplant surgery
Sussman, Jon , Calderon, Esteban , Ubl, Daniel S. , Croome, Kristopher P. , Moss, Adyr A. , Habermann, Elizabeth B. , Mathur, Amit K. , Taner, C. Burcin , Mathur, Amit , Croome, Kris P , Habermann, Elizabeth , Calderon, Esteban , Heimbach, Julie K.

Mayo Clinic

Clinical Transplantation | July 23, 2021 | Volume: 35 | Issue: 10 | Pages: No page available

10.1111/ctr.14439 | PMID 34297440 Get It

AbstractBackgroundOpioids are associated with negative transplant outcomes. We sought to identify patient and center effects on over‐prescribing of opioids (> 200 OME (oral morphine equivalents)).Study designClinical and opioid prescription data (2014–2017) were collected from three academic transplant centers for kidney (KT), liver (LT), and simultaneous liver‐kidney transplant (SLK) patients. Multivariable models were used to identify predictors of opioid over‐prescribing at discharge and the occurrence of refill prescriptions at 90 days.ResultsThree‐thousand seven‐hundred and two patients underwent transplant in the cohort (KT: n = 2358, LT: n = 1221, SLK: n = 123). More than 80% of recipients were over‐prescribed opioids at discharge (Median OME (mOME) = 300 (IQR 225–375). LT and SLK had the largest prescription size (LT mOME 338 (IQR 300–450); SLK mOME 338 (IQR 225–450) and refill rate (LT: 64%, SLK 59%) (all, P < .001). Multivariable analysis indicated that transplant center was a significant predictor of opioid over‐prescription after KT and LT (all, P < .001); older age (in KT) and length of stay (LOS) (in LT) were protective factors (both, P < .05). Refill occurrence was associated with initial prescription size and was reduced by older age and initial LOS (all, P < .05).ConclusionsThe wide variation in opioid prescribing patterns has implications for transplant practice innovation, guideline development, and further study.